CytoAgents, Inc

Cytokines play a critical role in enabling the immune system to protect the body from diseases and other sources of potential injury. Immune cells produce cytokines to activate and recruit other immune cells to help eliminate threats. These immune cells in turn produce their own cytokines to amplify this signal, recruiting more cells and creating a feedback loop resulting in a targeted inflammatory response. Normally, the body balances this inflammatory response with a series of anti-inflammatory measures which downregulate the production of cytokines thereby restoring homeostasis. In the absence of adequate negative regulation, cytokine production and activation can spiral out of control, causing excessive systemic inflammation and leading to the dangerous condition of Cytokine Release Syndrome (CRS). CytoAgents’ approach to treating CRS focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines while leaving necessary immune functions intact. Learn more: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines Teresa Whalen, RPh

As scientists continue to seek ways to expand the use of CAR T-cell therapy, it is more essential than ever to address serious risks associated with this type of treatment. More than two-thirds of CAR T-cell patients experience a potentially life-threatening side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. CytoAgents is developing a safe and effective treatment for CRS. Learn about it here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

CytoAgents' CEO, Teresa Whalen, RPh, leads a team of world-renowned clinical drug development experts and scientific advisory board members who are at the forefront of groundbreaking treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. Meet our team here: https://lnkd.in/g7P29x3i #leadership #biotechnology #biotech #healthcareleadership

Cytokine Release Syndrome (CRS) is an overreaction of the immune system caused by excessive, prolonged cytokine production. It can be triggered by a wide range of indications, including viral and bacterial infections, autoimmune disorders, traumatic brain injury, as well as modern immunotherapies such as CAR T-cell therapy and Bispecific Antibodies. CytoAgents’ approach to treatment focuses on rebalancing the immune system by reducing the destructive impact of excessive cytokines while leaving necessary immune functions intact. Learn more: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #cytokines #crs Teresa Whalen, RPh

Researchers are continually seeking ways to improve the efficacy and safety of CAR T-cell therapy for the treatment of certain types of cancer. One major areas of concern is a potentially life-threatening side effect known as Cytokine Release Syndrome (CRS), which is experienced by more than two-thirds of CAR T-cell therapy patients. Learn how CytoAgents is striving to make CAR T-cell therapy safer for cancer patients: https://lnkd.in/eFasArrf #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

2024 has been an exceptional year so far for CytoAgents. In addition to CytoAgents' recent $2M grant from The National Institutes of Health (NIH) and being named a TECH 50 Life Sciences Finalist by the Pittsburgh Technology Council & Fortyx80, our CEO Teresa Whalen, RPh has made several key industry presentations, appeared on Our Region's Business on WPXI-TV, and is a TECH 50 finalist for CEO of the Year! We look forward to many more successes as we head into the final quarter of 2024. Stay tuned! #biotechnology #biotech #healthcareleadership #innovation #pittsburgh

CytoAgents is conducting its Phase 1b/2a clinical trial to treat Cytokine Release Syndrome (CRS) in patients receiving CAR T-cell therapy in oncology. Immunotherapies such as CAR T and Bispecific Antibodies trigger powerful immune responses to fight disease, which often induce CRS. With support from the investment and healthcare communities, CytoAgents is poised to make a significant impact in improving patient outcomes and expanding access to important treatment modalities. Learn more about CytoAgents and CRS here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cyrokines #cartcelltherapy Teresa Whalen, RPh

In this article, Dr. Madiha Iqbal, a hematologist and?oncologist with the Mayo Clinic, provides a succinct overview of chimeric antigen receptor (CAR) T-cell therapy. While this revolutionary approach to treating certain types of cancer has helped to improve patient outcomes, there are still risks associated with CAR T-cell therapy, including Cytokine Release Syndrome (CRS), which is a potentially life-threatening overreaction of the immune system. Learn how CytoAgents is leading the charge in developing a safe and effective treatment for CRS: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

We are very excited about being named a TECH 50 Life Sciences Finalist once again! And we are proud of our CEO, Teresa Whalen, RPh, who is a finalist for CEO of the Year. Thank you Pittsburgh Technology Council & Fortyx80 for this honor.

We are excited to announce that CytoAgents has been awarded a $2 million grant from The National Institutes of Health (NIH), our third NIH grant in four years. This funding will accelerate the development of our lead drug candidate, CTO1681, an investigational new drug that uses a novel approach designed to prevent and mitigate Cytokine Release Syndrome (CRS) in patients receiving CAR T-cell therapy. You can read the full news release here: https://lnkd.in/eU-7GFT8 Catherine Mott Boston Harbor Angels Ziad Henry Moukheiber BlueTree Allied Angels Next Act Fund LLC Christine Tandon #CytokineReleaseSyndrome #CRS #CARTCellTherapy